← Back to Search

Prostaglandin Analog

Bimatoprost SR for Glaucoma

Phase 3
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Diagnosis of either Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 48 months
Awards & highlights

Study Summary

This trial looks at the long-term effects and safety of using a medication to lower eye pressure in people with glaucoma or ocular hypertension.

Who is the study for?
This trial is for people with open-angle glaucoma or ocular hypertension who need treatment to lower their eye pressure but can't use topical medication effectively. Participants should not have used Bimatoprost SR before or been in another drug/device study within the last 2 months.Check my eligibility
What is being tested?
The study tests how long the effect of Bimatoprost sustained release (SR) lasts in lowering intraocular pressure and its safety when given as needed to patients with open-angle glaucoma or ocular hypertension.See study design
What are the potential side effects?
Possible side effects of Bimatoprost SR include red eyes, eye irritation, skin darkening around the eyes, eyelash growth, and potential changes in eye color. These are based on known effects of similar treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have glaucoma or high eye pressure needing treatment.
Select...
I have glaucoma or high eye pressure needing treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 48 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 48 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients experiencing a treatment emergent adverse event
Retreatment or rescue administered for IOP

Trial Design

2Treatment groups
Experimental Treatment
Group I: Bimatoprost SR - Dose BExperimental Treatment1 Intervention
Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR.
Group II: Bimatoprost SR - Dose AExperimental Treatment1 Intervention
Study Eye: Participants will receive 1 - 2 Cycles of Bimatoprost SR administrations of Dose A Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR.

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,054 Total Patients Enrolled
85 Trials studying Ocular Hypertension
50,767 Patients Enrolled for Ocular Hypertension
AbbVieLead Sponsor
954 Previous Clinical Trials
500,590 Total Patients Enrolled
4 Trials studying Ocular Hypertension
973 Patients Enrolled for Ocular Hypertension
ABBVIE INC.Study DirectorAbbVie
394 Previous Clinical Trials
145,424 Total Patients Enrolled
4 Trials studying Ocular Hypertension
973 Patients Enrolled for Ocular Hypertension

Media Library

Bimatoprost (SR) (Prostaglandin Analog) Clinical Trial Eligibility Overview. Trial Name: NCT03850782 — Phase 3
Ocular Hypertension Research Study Groups: Bimatoprost SR - Dose B, Bimatoprost SR - Dose A
Ocular Hypertension Clinical Trial 2023: Bimatoprost (SR) Highlights & Side Effects. Trial Name: NCT03850782 — Phase 3
Bimatoprost (SR) (Prostaglandin Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03850782 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Bimatoprost (SR) used to treat?

"Bimatoprost (SR) is an effective medical treatment for open angle glaucoma, increased intra ocular pressure, and eyelash."

Answered by AI

What is unique about this clinical trial?

"Bimatoprost (SR) has been under clinical observation since 2015. The first Phase 3 drug trial was sponsored by Allergan and took place that same year. Since then, there have been 5 active trials in 31 countries and 152 cities."

Answered by AI

Could you explain the possible adverse effects of Bimatoprost (SR)?

"There is some evidence to support the efficacy of Bimatoprost (SR), as this drug is in Phase 3 trials. Furthermore, multiple rounds of data have been collected to support its safety, scoring it a 3 on our team's risk assessment scale."

Answered by AI

Is Bimatoprost (SR) a common medication in other research?

"First appearing in medical literature in 2015, bimatoprost (SR) has been part of 110 completed clinical trials. There are 5 more active studies involving this medication, several of which are based out of Danbury, Connecticut."

Answered by AI

Is this trial widely available in urban areas?

"This particular trial is being conducted by Danbury Eye Physicians & Surgeons P.C. /ID# 234981 in Danbury, Connecticut, Eye Research Foundation /ID# 234521 in Newport Beach, California, and Glaucoma Specialists of South Florida /ID# 235784 in Delray Beach, Florida with other medical centres spread out across 40 different locations."

Answered by AI

How many people are being signed up for this trial?

"The clinical trial is admitting 490 participants between 40 locations."

Answered by AI

Are we currently enrolling people in this trial?

"That is correct. The clinical trial was posted on February 28th, 2019 and last edited November 15th, 2020. Currently, the study is looking for 490 participants across 40 different sites."

Answered by AI

Who else is applying?

What state do they live in?
California
Michigan
Massachusetts
Other
How old are they?
< 18
65+
18 - 65
What site did they apply to?
Global Research Foundation /ID# 237350
Other
Eye Clinic University of Catania /ID# 235573
Byers Eye Institute Stanford /ID# 235544
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

Why did patients apply to this trial?

I was diagnostic with glaucoma.
PatientReceived 2+ prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Walman Eye Center /ID# 235240: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
2019. "Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03850782.
All > Glaucoma Long Beach > Latisse
~100 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top